These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28522137)

  • 1. Significance of change in serum bilirubin in predicting left ventricular reverse remodeling and outcomes in heart failure patients with cardiac resynchronization therapy.
    Hosoda J; Ishikawa T; Matsumoto K; Iguchi K; Matsushita H; Ogino Y; Taguchi Y; Sugano T; Ishigami T; Kimura K; Tamura K
    J Cardiol; 2017 Nov; 70(5):416-419. PubMed ID: 28522137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.
    Gold MR; Daubert C; Abraham WT; Ghio S; St John Sutton M; Hudnall JH; Cerkvenik J; Linde C
    Heart Rhythm; 2015 Mar; 12(3):524-530. PubMed ID: 25460860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of secondary mitral regurgitation in patients with heart failure receiving cardiac resynchronization therapy: Impact on long-term outcome beyond left ventricular reverse remodelling.
    Binda C; Menet A; Appert L; Ennezat PV; Delelis F; Castel AL; Le Goffic C; Guyomar Y; Ringlé A; Guerbaai RA; Graux P; Tribouilloy C; Maréchaux S
    Arch Cardiovasc Dis; 2018 May; 111(5):320-331. PubMed ID: 29102366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.
    Park JH; Negishi K; Grimm RA; Popovic Z; Stanton T; Wilkoff BL; Marwick TH
    Circ Cardiovasc Imaging; 2013 Nov; 6(6):864-72. PubMed ID: 24084489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).
    St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B
    J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dyssynchrony.
    Carluccio E; Biagioli P; Alunni G; Murrone A; Pantano P; Biscottini E; Zuchi C; Zingarini G; Cavallini C; Ambrosio G
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1067-76. PubMed ID: 21999865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology.
    Martens P; Nijst P; Verbrugge FH; Dupont M; Tang WHW; Mullens W
    Heart Rhythm; 2018 Jan; 15(1):130-136. PubMed ID: 28843420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial.
    St John Sutton M; Linde C; Gold MR; Abraham WT; Ghio S; Cerkvenik J; Daubert JC;
    JACC Heart Fail; 2017 Mar; 5(3):169-178. PubMed ID: 28254122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin is associated with reverse remodeling after cardiac resynchronization therapy in patients with heart failure and ventricular dyssynchrony.
    Dominguez-Rodriguez A; Abreu-Gonzalez P; Piccolo R; Galasso G; Reiter RJ
    Int J Cardiol; 2016 Oct; 221():359-63. PubMed ID: 27404706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.
    Gold MR; Thébault C; Linde C; Abraham WT; Gerritse B; Ghio S; St John Sutton M; Daubert JC
    Circulation; 2012 Aug; 126(7):822-9. PubMed ID: 22781424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial.
    Khan FZ; Virdee MS; Palmer CR; Pugh PJ; O'Halloran D; Elsik M; Read PA; Begley D; Fynn SP; Dutka DP
    J Am Coll Cardiol; 2012 Apr; 59(17):1509-18. PubMed ID: 22405632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanical abnormalities detected with conventional echocardiography are associated with response and midterm survival in CRT.
    Doltra A; Bijnens B; Tolosana JM; Borràs R; Khatib M; Penela D; De Caralt TM; Castel MÁ; Berruezo A; Brugada J; Mont L; Sitges M
    JACC Cardiovasc Imaging; 2014 Oct; 7(10):969-79. PubMed ID: 25240452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
    Linde C; Gold MR; Abraham WT; St John Sutton M; Ghio S; Cerkvenik J; Daubert C;
    Eur Heart J; 2013 Sep; 34(33):2592-9. PubMed ID: 23641006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Cardiac Resynchronization Therapy on Myocardial Fibrosis and Relevant Cytokines in a Canine Model With Experimental Heart Failure.
    Wang J; Gong X; Chen H; Qin S; Zhou N; Su Y; Ge J
    J Cardiovasc Electrophysiol; 2017 Apr; 28(4):438-445. PubMed ID: 28127817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy.
    Hosoda J; Ishikawa T; Matsushita K; Matsumoto K; Kimura Y; Miyamoto M; Ogawa H; Takamura T; Sugano T; Ishigami T; Uchino K; Kimura K; Umemura S
    J Cardiol; 2012 Oct; 60(4):301-5. PubMed ID: 22763383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic benefit of optimum left ventricular lead position in cardiac resynchronization therapy: follow-up of the TARGET Study Cohort (Targeted Left Ventricular Lead Placement to guide Cardiac Resynchronization Therapy).
    Kydd AC; Khan FZ; Watson WD; Pugh PJ; Virdee MS; Dutka DP
    JACC Heart Fail; 2014 Jun; 2(3):205-12. PubMed ID: 24952685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathoracic impedance changes reflect reverse left ventricular remodeling in response to cardiac resynchronization therapy in chronic heart failure patients.
    Kaneshiro T; Suzuki H; Yamada S; Kamiyama Y; Saitoh S; Takeishi Y
    Int Heart J; 2012; 53(4):249-52. PubMed ID: 22878804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.
    Hsu JC; Solomon SD; Bourgoun M; McNitt S; Goldenberg I; Klein H; Moss AJ; Foster E;
    J Am Coll Cardiol; 2012 Jun; 59(25):2366-73. PubMed ID: 22698490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of myocardial viability and left ventricular lead location on clinical outcome in cardiac resynchronization therapy recipients with ischemic cardiomyopathy.
    Bose A; Kandala J; Upadhyay GA; Riedl L; Ahmado I; Padmanabhan R; Gewirtz H; Mulligan LJ; Singh JP
    J Cardiovasc Electrophysiol; 2014 May; 25(5):507-513. PubMed ID: 24350650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Mullens W
    Am J Cardiol; 2017 Jul; 120(2):267-273. PubMed ID: 28532770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.